Stromal vascular fraction, usually shortened to SVF, is one of the most commercialized names in regenerative medicine, and also one of the most misunderstood. It is often introduced to patients as a same day stem cell therapy, pulled from the patient's own fat and injected back in during a single visit. In practice, SVF is a specific cell fraction with a narrow surgical role, a clear regulatory boundary, and real limits that shape what it can and cannot do.

What Is SVF?

SVF is the pellet of cells left at the bottom of a centrifuge tube after liposuction fat is processed. Adipose tissue contains a mixed population of cells, and when that tissue is broken down and spun down, the heavier cells settle into a small fraction at the base of the tube. That fraction is what the industry calls the stromal vascular fraction.

Collection is a surgical procedure. A plastic surgeon performs a small liposuction harvest, usually from the stomach, low back, or thighs. A common reference volume is around fifty cubic centimeters of fluid. That fluid is then processed in a centrifuge, and the pellet at the bottom is isolated and considered the final cell product.

A typical SVF collection is small in cellular terms. Documented values put the final product at roughly fifty thousand cells per fifty cubic centimeters of fluid, with average live cell viability around fifty six percent depending on the pressure used during the harvest. That puts a natural ceiling on how many cells are inside a single collection.

How It All Started

SVF as a modern therapy begins with one laboratory and one paper. In 2001, a team led by Dr. Patricia Zuk at the University of California, Los Angeles, published a study in Tissue Engineering showing that human fat contains a population of cells that can differentiate into multiple tissue types. A follow up paper in 2002 in Molecular Biology of the Cell confirmed that adipose tissue is a practical source of multipotent cells, and that those cells could be harvested from a standard liposuction procedure.

That work opened a door. Fat was easy to collect, patients had plenty of it, and the same day surgical model looked like a faster path to the clinic than the traditional bone marrow pathway. Over the next decade, clinics around the country built their programs around adipose derived SVF, and for a period the category defined what the general public understood as stem cell therapy.

What SVF Has Done for Patients

In the years after those first papers, SVF became a common component of same day orthopedic procedures. Surgeons use it for joint injections, soft tissue repair, and similar indications that can be completed inside a single operating room visit. The core legal pathway for that use is the same surgical procedure exemption in 21 CFR 1271.15, which allows a patient's own cells to be removed, processed in a minimal way, and returned to the same patient during the same procedure.

Outside of that same surgical setting, the picture changes sharply. The FDA has taken the position that SVF prepared with enzymatic digestion is more than minimally manipulated, which moves it into drug regulation. Federal court decisions in cases involving California Stem Cell Treatment Center and US Stem Cell Inc. confirmed that position and upheld enforcement action against clinics offering SVF outside the same procedure exemption. What began as a promising laboratory finding had become a tightly bounded surgical tool. For patients who fit that surgical use case, SVF has been a real option.

Autism is a separate story. SVF has never been approved for autism, and there is no large randomized clinical trial that supports its use for autism spectrum disorder. Families searching online still encounter clinics offering adipose stem cell injections as a treatment for autism, and the FDA has issued public warnings and pursued court action against companies marketing SVF for neurological and systemic conditions it is not approved to treat.

The practical challenges stack on top of that. A single SVF collection yields on the order of fifty thousand cells per fifty cubic centimeters of fluid with average viability around fifty six percent, which is small compared to the doses used in most cellular therapy programs. SVF is not designed for storage, so the material is meant to be used inside the same surgical setting rather than staged over multiple treatments. SVF is also not designed or approved for IV infusion, which is the delivery format most autism focused cellular programs are built around. For families looking specifically at autism care, SVF has not been shown to work, is not approved for the purpose, and does not fit the infusion and repeat treatment model those families are usually considering.

Limits a Patient Should Weigh

Use outside same day surgery is considered a drug. The same surgical procedure exemption covers SVF only when the cells are removed, processed, and returned during a single procedure on the same patient. Any use outside that window, including storing the cells for a later visit or shipping them to a different facility, moves the product under drug regulation and has been the basis for FDA enforcement action.

Average live cell viability is around fifty six percent. Documented values put viability near the midpoint of the scale, and the number can fall further depending on the pressure used during the liposuction harvest. A patient and physician who are planning around a specific live cell dose are working from a variable starting number.

Total cell counts are small. A reference harvest of fifty cubic centimeters yields about fifty thousand cells in the final pellet. That is a fraction of the doses typical of other cellular therapy programs.

SVF is not designed for storage. The workflow assumes same time surgical use. A patient whose plan would call for multiple doses over months or years cannot rely on a single liposuction harvest to cover staged treatment, because the material is not built to be banked and released later.

SVF is not designed for IV infusion. The product is positioned for injection during a surgical procedure, not for systemic IV delivery. A patient looking for an IV cellular therapy will not find SVF on the approved list for that format.

The harvest requires a surgical procedure. Liposuction is safe in experienced hands, but it is still a surgical event with the bruising, swelling, and recovery time that go with it. A patient is scheduling a procedure, not a blood draw.

Approved uses are narrow. SVF is used primarily in same day orthopedic injection settings. It has not been approved for most of the chronic conditions families hear about in connection with stem cells, such as ongoing care for neurological conditions or degenerative diseases. A patient looking for cellular therapy outside the same day surgical setting will generally not find SVF on the list of options.

A New Frontier: Neuro Free

For families looking at cellular therapy as part of autism care, one of the newer developments in the United States is Neuro Free. It is the only U.S. based patented cellular therapy developed specifically for autism spectrum disorder, aimed at improving brain function and reducing neurological inflammation in pediatric and young patients with autism. Treatment is available for ages 2 to 22, with most patients treated between 2 and 20.

Neuro Free was founded in 2016 by physicians who had watched families travel overseas in search of stem cell options they could not find at home. Those trips were often expensive, emotionally difficult, and carried out with limited medical oversight. The program was built to offer that pathway inside a physician led setting in the United States and Canada.

A treatment cycle begins with tissue donated by the mother and collected by a plastic surgeon. The harvest is then developed through a patented process carried out inside an FDA registered laboratory, with the patent and the laboratory held by separate entities. On treatment day, the cells are delivered to the child through an IV infusion that runs for about two and a half hours. Many children report feeling sleepy during the infusion, there are no known side effects, and noticeable changes are typically reported within a few hours of treatment.

Several points set the Neuro Free program apart from SVF:

• Cells taken from their natural source. The program works from the perivascular fraction, the layer along the outside of blood vessels where mesenchymal stem cells naturally reside, rather than isolating a centrifuge pellet as the final cell fraction.
• Higher cell counts and viability. A typical Neuro Free unit carries 30 to 90 million cells with live cell viability typically reported between 95 and 100 percent. A typical SVF harvest yields about 50,000 cells with average viability around 56 percent.
• Documented cell counts. Each unit is released with recorded total nucleated cells, total cells, and live cell viability. SVF workflows are not built around patient facing count reporting in the same way.
• Repeatable treatment. The full harvest is processed and stored at negative 80 degrees Celsius, and doses are released on request. A child's care plan can include multiple scheduled infusions rather than a single same day procedure.
• Designed for injection and infusion. The program is built for both IV infusions and injections, rather than being limited to same time surgical settings where SVF is approved for use.

Sources

• Zuk, P. A., et al. "Multilineage Cells from Human Adipose Tissue: Implications for Cell Based Therapies." Tissue Engineering, 2001.
• Zuk, P. A., et al. "Human Adipose Tissue Is a Source of Multipotent Stem Cells." Molecular Biology of the Cell, 2002.
• U.S. Food and Drug Administration. "21 CFR 1271.15: Are There Any Exceptions from the Requirements of This Part?"
• U.S. Food and Drug Administration. "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue Based Products: Minimal Manipulation and Homologous Use." Guidance for Industry.
• U.S. Department of Justice. "Court Issues Permanent Injunction Against California Stem Cell Clinic."
• U.S. Food and Drug Administration. "Important Patient and Consumer Information About Regenerative Medicine Therapies."